Skip to main content
Erschienen in: World Journal of Surgical Oncology 1/2017

Open Access 01.12.2017 | Research

The efficacy and feasibility of total reconstruction versus nontotal reconstruction of the pelvic floor on short-term and long-term urinary continence rates after radical prostatectomy: a meta-analysis

verfasst von: Yu-Peng Wu, Ning Xu, Shi-Tao Wang, Shao-Hao Chen, Yun-Zhi Lin, Xiao-Dong Li, Qing-Shui Zheng, Yong Wei, Xue-Yi Xue

Erschienen in: World Journal of Surgical Oncology | Ausgabe 1/2017

Abstract

Background

Recently, total pelvic floor reconstruction (TR) has been the treatment of choice for improving urinary incontinence (UI) after radical prostatectomy (RP). However, the superiority of TR with respect to urinary continence recovery following RP remains controversial. This study identified the effect of TR versus nonTR of the pelvic floor on short-term and long-term continence rates after RP.

Methods

A literature search was performed in November 2017 using the PubMed, Embase, and Web of Science databases. Only comparative research or clinical studies reporting urinary continence outcomes was included in the meta-analysis, and the quality of evidence was evaluated using the 2011 Level of Evidence for therapy research.

Results

We analyzed ten studies reporting urinary continence rates after RP at one or more postoperative time points (1, 2, 4, 12, 24, and 52 weeks). TR was associated with significantly better urinary continence outcomes at 1 week (OR 2.76, 95% CI 1.58–4.84, P < 0.001), 2 weeks (OR 2.57, 95% CI 1.74–3.80, P < 0.001), 4 weeks (OR 2.61, 95% CI 1.56–4.38, P < 0.001), 12 weeks (OR 4.33, 95% CI 2.01–9.33, P < 0.001), 24 weeks (OR 3.83, 95% CI 1.54–9.55, P = 0.004), 52 weeks (OR 4.10, 95% CI 1.80–9.38, P < 0.001) after RP. There was no difference in the rate of complications between the two arms (OR 0.54, 95% CI 0.19–1.54, P = 0.25).

Conclusions

Compared with nonTR, TR is significantly and positively associated with a return to continence but not with complication rate in men following RP, suggesting that TR may be useful for decreasing the urinary incontinence rate after surgery.

Background

Radical prostatectomy (RP) remains the standard surgical strategy for localized prostate cancer [1, 2]. Urinary incontinence (UI) is one of the most distressing complications of RP. The long-term continence rate varies from 66.7 to 97% at 48 weeks after laparoscopic radical prostatectomy (LRP) and robot-assisted radical prostatectomy (RARP). However, the short-term continence rate varies from 17 to 89% at 12 weeks [3, 4]. Apparently, achieving short-term continence is challenging and has a great impact on the health-related quality of life (QoL) of patients [5, 6].
Recently, several technical modifications to improve postoperative continence have been described, including intraoperative maximization of membranous urethral length [7], the dorsal vein complex-preserving technique [8], intrafascial nerve-sparing [4, 9, 10], preservation of the puboprostatic collar [11], anterior reconstruction [12, 13], posterior reconstruction [1416], and anterior plus posterior reconstruction [17, 18]. The anterior or posterior reconstruction and total pelvic floor reconstruction (TR) (anterior plus posterior reconstruction) techniques are reported to be simpler than the others among these modifications. The surgical techniques in different studies are varied (Table 1). In a study by Hoshi et al., the TR technique was described in two parts: anterior reconstruction of the detrusor apron and posterior reconstruction of the musculofascial plate [10]. TR has become widespread because this technique is simpler and has a favorable effect on early recovery from incontinence. The time to return to continence after RP in published studies varies [9, 1820]. Four previous randomized controlled trials (RCTs) showed inconsistent results 4 weeks after surgery. Hurtes et al. [20] and Koliakos et al. [21] demonstrated TR had a statistically significant advantage. In contrast, Menon et al. [22] demonstrated similar outcomes in participants who received TR management and those who received nonTR management. Moreover, Hoshi et al. [10] demonstrated a significant advantage in favor of TR in terms of long-term (48 weeks) continence rates. However, Sammon et al. [23] showed TR did not result in improvement in long-term continence rates. Therefore, we performed a meta-analysis to evaluate the effect of TR versus nonTR management on short- and long-term continence rates after RP.
Table 1
Preserved relevant anatomy facilitating reconstruction
Study ID
Puboprostatic ligaments
Pubovesical collar
Arcus tendineus
Rhabdosphincter
Denonvillier’s fascia
Bladder neck
Median dorsal raphe
Student [27], 2017
+
+
+
+
+
+
Liao [19], 2016
+
+
+
+
+
+
Atug [25], 2012
+
+
+
Hoshi [10], 2014
+
+
+
+
+
Hurtes [20], 2012
+
+
+
+
Menon [22], 2008
+
+
+
+
+
Tewari [18], 2007
+
+
+
+
+
+
Koliakos [21], 2009
+
+
+
+
Tan [26], 2010
+
+
+
+
+
+
Sammon [23], 2010
+
+
+
+

Methods

Ethics statement and objective

Ethical approval was not required for this meta-analysis because it did not affect the participants directly. The aim of this meta-analysis was to identify the effect of TR versus nonTR management on short- and long-term urinary continence rates after RP.

Search strategy

PubMed, Embase, and Web of Science databases were searched for relevant articles from the inception of each database through November 2, 2017. The PubMed was searched using the combined terms “prostatectomy OR radical prostatectomy AND urinary continence AND anterior or posterior OR total OR complete AND reconstruction OR restoration OR anastomosis OR fixation OR puboperineoplasty in the title and abstract. Embase and Web of Science databases were searched using the same combined terms, keywords, and search strategy.

Study selection

Two investigators (Yu-Peng Wu and Shi-Tao Wang) extracted data employing a predefined data extraction form. Subsequent full-text record screening was performed independently by two investigators (Yu-Peng Wu and Shi-Tao Wang). Disagreements were resolved by a third reviewer (Ning Xu) [1]. Full-text articles were obtained to determine eligibility when the information from the title or abstract was insufficient. Reference lists of relevant studies were also manually searched to identify articles not found in the search strategies. Studies were included and excluded according to the criteria presented in Table 2.
Table 2
Inclusion and exclusion criteria
Inclusion criteria
Exclusion criteria
Men undergoing RP
Review articles and descriptive commentaries
Studies reporting TR versus nonTR
Animal studies
Postoperative continence assessment completed
Conference abstracts or poster publications
English language
Published in a language other than English
Full journal article publication in a peer-reviewed journal
 

Quality assessment

All included studies were categorized based on the 2011 Level of Evidence for therapy research as a systematic review of randomized trials (level 1); randomized trial or observational study with dramatic effects (level 2); nonrandomized controlled cohort/follow-up study (level 3); case series, case-control study, or historically controlled study (level 4); or mechanism-based reasoning (level 5) [24].

Data extraction and synthesis

Data extracted from each comparative study included study characteristics and preoperative parameters, perioperative outcome measures, complications, and pathological results continence definition, data collection, and, when available, the 1-, 2-, 4-, 12-, 24, and 52-week urinary continence rates.

Meta-analysis methods

Meta-analysis was conducted using the RevMan 5.3 software (Cochrane Collaboration, Oxford, UK). Statistical heterogeneity was evaluated using the chi-square test. If no heterogeneity existed when P > 0.1 and I 2 < 50%, a fixed-effects model was applied to pool the trial results. Significant heterogeneity was identified if P < 0.1 and I 2 > 50%, and a random-effects model was employed [2]. Sensitivity analysis was then done to determine whether the use of the excluded study would alter the results substantially. The cumulative outcomes of dichotomous variables were determined using odds ratios (ORs) and 95% confidence intervals (CIs). P < 0.05 was considered statistically significant.

Results

Figure 1 shows the PRISMA flow diagram for the study selection process. The searches retrieved 365 citations. After removal of duplicates and review of the abstracts and full-text articles, ten studies including 12 trials were eligible for inclusion in this meta-analysis. All corresponding authors were contacted via email to provide clarification and/or additional data when necessary. At least three follow-up attempts were made for queries sent; unfortunately, these attempts were unsuccessful.

Quality assessment

The remaining 12 trials included 7 RCTs (58.3%) (level 2), 2 prospective comparative trials (PTs) (16.7%) (level 3), and 3 retrospective comparative trials (RTs) (25.0%) (level 4).

Characteristics of the studies included

Patient and surgical characteristics

Participant and surgical characteristics are presented in Tables 3, 4, and 5. A total of ten studies [10, 1823, 2527] comprising 12 trials reported the continence rate. For the study reporting the continence rate at 1 week, a total of five studies [18, 19, 22, 25, 26] comprising six trials were included; urinary continence was defined as 0 pads in two trials [19, 22] and as 0 pads or 1 pad used for safety (0–1 for safety) in four trials [18, 22, 25, 26]. For the study reporting the continence rate at 2 weeks, a total of four trials [19, 20, 25, 27] were included; urinary continence was defined as 0 pads in three trials [19, 20, 27] and 0–1 for safety in one trial [25]. For the study reporting the continence rate at 4 weeks, a total of ten studies [10, 1823, 2527] comprising 12 trials were included; urinary continence was defined as 0 pads in five trials [19, 20, 22, 23, 27] and 0–1 for safety in seven trials [10, 18, 2123, 25, 26]. For the study reporting the continence rate at 12 weeks, a total of six trials [10, 1820, 25, 26] were included; urinary continence was defined as 0 pads in two trials [19, 20] and 0–1 for safety in four trials [10, 18, 25, 26]. For the study reporting the continence rate at 24 weeks, a total of seven trials [10, 1820, 2527] were included; urinary continence was defined as 0 pads in three trials [19, 20, 27] and 0–1 for safety in four trials [10, 18, 25, 26]. For the study reporting the continence rate at 52 weeks, a total of five trials [10, 18, 19, 25, 26] were included; urinary continence was defined as 0 pads in one trial [19] and 0–1 for safety in four trials [10, 18, 25, 26].
Table 3
Study characteristics and preoperative parameters
Study ID
Country
Method
Sample
Age*, year
Prostate volume*, mL
IIEF-5 score, median (IQR)
IPSS
BMI* (kg/m2)
Preoperative PSA*, ng/mL
Nerve-sparing procedure, n (%)
Bilateral
Unilateral
Non
Student [27], 2017
Czech Republic
RARP
T
32
64.5 (56.0–67.0)
35.0 (30.0–55.0)
19.0 (13.5–21.0)
5.5 (2.0–9.3)
27.7 (25.7–33.2)
7.3 (5.2–11.2)
20 (62.5)
6 (18.75)
6 (18.75)
   
N
34
62.5 (61.0–68.0)
32.5 (22.0–52.0)
17.0 (13.3–21.0)
5.0 (2.8–14.0)
28.0 (25.4–31.4)
5.7 (3.6–12.0)
23 (67.6)
5 (14.7)
6 (17.6)
Liao [19], 2016
China
LRP
T
82
65.79 ± 7.27
42.06 ± 19.34*
7 (0~18)
24.26 ± 2.88
33.07 ± 40.65
27 (32.92)
19 (23.17)
36 (43.90)
   
N
79
67.88 ± 6.65*
41.92 ± 14.76*
6 (0~19)
25.35 ± 2.13
26.86 ± 31.95
16 (20.25)
28 (35.4)
35 (44.3)
Atug [25], 2012
Turkey
RARP
T
125
61.5 (9.5)
50 (24)
27 (4)
5.62 (3.65)
89 (71.2)
21 (16.8)
15 (12)
   
N
120
60.50 (11)
49.5 (25)
28 (4)
5.49 (2.92)
93 (77.5)
22 (18.3)
5 (4.2)
Hoshi [10], 2014
Japan
LRP
T
81
65.2 ± 5.6
9.2 ± 5.7
   
N
47
65.4 ± 4.4
11.8 ± 9.5
Hurtes [20], 2012
France
RARP
T
39
62.5 ± 6.8
38.5 (20–90)
20 (6–25)
5 (0–16)
26.3 ± 3.5
6.4 (2.7–16.6)
   
N
33
62.4 ± 5
40 (25–80)
23 (1–25)
7 (0–17)
25.7 ± 3.6
7.9 (3.6–23.6)
           
Standard^
Veil#
 
Menon [22], 2008
America
RARP
T
59
45.2*
27.9
6.1
37 (63)
22 (37)
   
N
57
63.4*
27.9
6.4
31 (54)
26 (46)
Tewari [18], 2007
America
RARP
T
182
61.21
50.53
24.98
5.76
   
N
214
64.32
57.12
28.77
6.02
Koliakos [21], 2009
Belgium
RARP
T
23
60.96 ± 6.56
10.43 ± 3.37
   
N
24
61.75 ± 5.96
10.47 ± 2.22
Tan [26], 2010
America
RARP
T
1383
60.3 ± 7.4
46 (38–56)
7 (3–12)
26.77 ± 3.59
4.8 (3.7–6.57)
   
N
214
59.8 ± 6.6
48 (39–63)
6 (2–11.25)
28.34 ± 5.57
4.8 (3.9–6.7)
           
Standard^
Veil#
Sammon [23], 2010
America
RARP
T
46
59.9 ± 7.4
28.3 ± 4.1
5.8 ± 66.3
23 (21)
21 (45.7)
   
N
50
60 ± 7.2
28 ± 4.21
5.7 ± 3.2
27 (54.0)
23 (46.0)
SD standard deviation, IQR interquartile range, IIEF International Index of Erectile Function 5, IPSS International Prostate Symptoms Score, BMI body mass index, PSA prostate specific antigen, T total reconstruction, N nontotal reconstruction, LRP laparoscopic radical prostatectomy, RARP robot-assisted radical prostatectomy
*Mean ± SD or median (IQR)
^Interfacial dissection: prostatic fascia excised with specimen
#Intrafacial dissection: prostatic fascia dissected off the prostate
Table 4
Perioperative outcome measures, complications, and pathological results
Study ID
Operative time*, min
Estimated blood loss*, mL
Duration of catheterization*, d
Complications, n (%)
PSM rate (%)
Total
pT2
pT3
Student [27], 2017
78.0 (63.0–126.0)#
145.0 (85.5–234.5)
2 (6.2)
4 (12.5)
 
76.5 (48.0–130.0)#
140.0 (80.0–294.0)
2 (5.8)
5 (14.7)
Liao [19], 2016
147.33 ± 29.89
232.63 ± 217.93
13.96 ± 2.20
36 (43.90)
13 (15.85)
 
130.81 + 21.66
225.42 ± 164.96
16.13 ± 16.47
35 (44.3)
10 (12.65)
Atug [25], 2012
175(55)
300 (200)
7 (0)
115 (92)
 
200(70)
350 (250)
7 (1)
110 (91.7)
Hoshi [10], 2014
240 (139–575)
228 (59–1340)
3 (3.7)
13 (16.0)
8 (11.8)
5 (38.5)
 
219(160–415)
236 (55–1875)
4 (8.5)
8 (17.0)
3 (7.7)
5 (62.5)
Hurtes [20], 2012
200 (100–400)
300 (100–1100)
6 (5–40)
8 (20.5)
8 (21.1)
 
220 (105–350)
300 (20–1500)
7 (5–20)
6 (18.2)
4 (12.1)
Menon [22], 2008
171
7
 
158
7
Tewari [18], 2007
104
140
7
7 (4.8)
 
132
150
<7
7 (3.8)
Koliakos [21], 2009
126.52 ± 11.48
225.65 ± 80.95
6.26 ± 0.96
 
124.54 ± 10.78
224.17 ± 64.06
6.17 ± 1.88
Tan [26], 2010
180 (150–230)
140 (140–150)
11 (0.8%)
65 (5.7)
 
187 (160–240)
150 (150–162.5)
13 (6.0%)
6 (3.2)
Sammon [23], 2010
174.1 ± 38.4
7.7 ± 2.4
 
165.2 ± 36
9.2 ± 4.2
PSM positive surgical margin
*Mean ± SD or median (IQR)
#Console time
Table 5
Clinical and pathological data of patients
Study ID
 
Clinical stage
Pathological stage
Gleason biopsy, n (%)
Gleason score, n (%)
cT1
cT2
cT3
pT0
pT1
pT2
pT3
< 7
7
> 7
< 7
7
> 7
Student [27], 2017
T 32
20 (62.5)
12 (37.5)
 
N 34
23 (67.6)
11 (32.4)
Liao [19], 2016
T 82
3 (3.7)
53 (64.6)
26 (31.7)
0
38 (46.3)
32 (39.0)
12 (14.6)
 
N 79
2 (2.5)
52 (65.8)
22 (27.8)
3 (3.8)
27 (34.2)
35 (44.3)
17 (21.5)
Atug [25], 2012
T 125
104 (82.9)
19 (15.5)
2 (1.6)
 
N 120
100 (83.1)
17 (14.4)
3 (2.5)
Hoshi [10], 2014
T 81
36 (44.4)
40 (49.4)
5 (6.2)
68 (84.0)
13 (16.0)
29 (35.8)
36 (44.4)
16 (19.8)
34 (42.0)
35 (43.2)
12 (14.8)
 
N 47
30 (63.8)
15 (31.9)
2 (4.3)
39 (83.0)
8 (17.0)
20 (42.6)
21 (44.7)
6 (12.8)
15 (31.9)
26 (55.3)
6 (12.8)
Hurtes [20], 2012
T 39
2 (5.1)
29 (74.4)
8 (20.5)
24 (61.5)
11 (28.2)
4 (10.3)
11 (28.2)
26 (66.7)
2 (5.1)
 
N 33
0
24 (72.7)
9 (27.3)
18 (54.6)
11 (33.3)
4 (12.1)
12 (36.4)
18 (54.5)
3 (9.1)
Tewari [18], 2007
T 182
147 (80.8)
30 (16.5)
5 (2.7)
146 (80.28)
18.77
0.46
 
N 214
161 (75.2)
51 (23.8)
2 (0.9)
186 (87.38)
11.21
0.93
Tan [26], 2010
T 1383
1250 (90.4)
133 (9.6)
0
1147 (82.9)
236 (17.1)
828 (59.9)
459 (33.2)
96 (6.9)
430 (31.1)
874 (63.2)
79 (5.7)
 
N 214
161 (75.2)
51 (23.8)
2 (0.9)
186 (86.9)
28 (13.1)
156 (72.9)
48 (22.4)
10 (4.7)
102 (47.4)
100 (46.9)
12 (5.6)

Definition of TR

The surgical technique for TR includes two components: one is a posterior reconstruction of the musculofascial plate and the other is an anterior reconstruction of the detrusor apron. In posterior reconstruction, the bladder neck, Denonvillier’s fascia, and the median dorsal raphe are sutured together before anastomosis. In anterior reconstruction, the bilateral puboprostatic ligaments and pudendal arteries are preserved, and the detrusor apron and puboprostatic ligament collar are reconstructed after vesicourethral anastomosis [10].

Definition of UI

All studies reported the definition of continence and method of assessment used. Eleven of the 12 trials reported similar methods of assessing postoperative UI using questionnaires. Only one trial assessed the postoperative UI using interview data. Six studies [10, 18, 21, 23, 25, 26] comprising seven trials defined continence as 0–1 pad used, and five trials [19, 20, 22, 23, 27] defined continence as 0 pads used.

Outcomes

Table 6 summarizes the data of the 12 trials comparing TR versus nonTR in terms of continence definition, method of data collection, and continence rates.
Table 6
Continence definition, data collection, and continence rates
Study ID
Study design
Continence definition
Data collection
 
Cases, n
1 week
2 weeks
4 weeks
12 weeks
24 weeks
52 weeks
Student [27], 2017
RCT
0 pad
Validated questionnaire
T
32
43.8
62.5
75.0
    
N
34
11.8
14.7
44.1
Liao [19], 2016
Retrospective
No leak, total control, no pad
Validated questionnaire
T
82
13.41
32.92
65.85
81.71
90.24
95.12
    
N
79
7.59
20.25
37.97
58.22
81.01
89.87
Atug [25], 2012
Retrospective
0–1 safety pad
Interview
T
125
71.2
72.8
80.8
84.8
86.4
91.2
    
N
120
23.33
49.1
76.6
80.8
85.83
88.33
Hoshi [10], 2014
Retrospective
0–1 safety pad
Validated questionnaire
T
81
18.4
45.7
71.4
    
N
47
4.5
26.1
46.8
Hurtes [20], 2012
RCT
No leak, total control, no pad
Validated questionnaire
T
39
5.9
26.5
45.2
65.4
    
N
33
3.6
7.1
15.4
57.9
Menon1 [22], 2008
RCT
0–1 safety pad
Validated questionnaire
T
59
54
80
    
N
57
51
74
Menon2 [22], 2008
RCT
0 pad
Validated questionnaire
T
59
20
42
    
N
57
16
47
Tewari [18], 2007
Prospective
0–1 safety pad
Validated questionnaire
T
182
38.37
82.56
91.3
97.14
97.14a
    
N
214
13.15
35.21
50.23
61.97
82.16
Koliakos [21], 2009
RCT
0–1 safety pad
Validated questionnaire
T
23
65
    
N
24
33
Tan [26], 2010
Prospective
0–1 safety pad
Validated questionnaire
T
1383
30.8
70
91.7
95
98
    
N
214
13.1
35.2
50.2
61.9
82.1
Sammon1 [23], 2010
RCT
0–1 safety pad
Validated questionnaire
T
46
42
    
N
50
47
Sammon2 [23], 2010
RCT
0 pad
Validated questionnaire
T
46
80
    
N
50
74
RCT randomized controlled trial, weeks week; T total reconstruction, N nontotal reconstruction
aThe 52-week urinary continence rate was not reported directly in the study of Tewari, [18]. Thus, the urinary continence rate at 24 weeks was represented as the urinary continence rate at 52 weeks

Return of continence at 1 week

Five studies [18, 19, 22, 25, 26] comprising six trials reported the number of people returning to continence at 1 week. In the 0-pad subgroup, the cumulative results showed no statistically significant difference between the TR and nonTR groups in terms of return to continence at 1 week (OR 1.58, 95% CI 0.78 to 3.19; P = 0.20). In the 0–1 for safety pad subgroup, the cumulative results showed a statistically significant difference in favor of TR 1 week after RP (OR 3.36, 95% CI 1.73 to 6.53; P < 0.001). The overall cumulative results showed a statistically significant difference in favor of TR 1 week after RP (OR 2.76, 95% CI 1.58–4.84; P < 0.001) (Fig. 2).

Return to continence at 2 weeks

Four trials [19, 20, 25, 27] reported the number of people returning to continence at 2 weeks. In the 0-pad subgroup, the cumulative results showed a statistically significant difference between the TR and nonTR groups in terms of return to continence at 2 weeks (OR 2.35, 95% CI 1.32 to 4.18; P = 0.004). In the 0–1 for safety pad subgroup, the cumulative results showed a statistically significant difference in favor of TR 2 weeks after RP (OR 2.77, 95% CI 1.63 to 4.71; P < 0.001). The overall cumulative results showed a statistically significant difference in favor of TR 2 weeks after RP (OR 2.57, 95% CI 1.74 to 3.80; P < 0.001) (Fig. 3).

Return to continence at 4 weeks

Ten studies [10, 1823, 2527] comprising 12 trials reported the number of people returning to continence at 4 weeks. In the 0-pad subgroup, the cumulative results showed a statistically significant difference between the TR and nonTR groups in terms of return to continence at 4 weeks (OR 2.59, 95% CI 1.11 to 6.04; P = 0.03). In the 0–1 for safety pad subgroup, the cumulative results showed a statistically significant difference in favor of TR 4 weeks after RP (OR 2.63, 95% CI 1.33 to 5.20; P = 0.005). The overall cumulative results showed a statistically significant difference in favor of TR 4 weeks after RP (OR 2.61, 95% CI 1.56–4.38; P < 0.001) (Fig. 4).

Return to continence at 12 weeks

Six trials [10, 1820, 25, 26] reported the number of people returning to continence at 12 weeks. In the 0-pad subgroup, the cumulative results showed a statistically significant difference between the TR and nonTR groups in terms of return to continence at 12 weeks (OR 3.59, 95% CI 1.96 to 6.59; P < 0.001). In the 0–1 for safety pad subgroup, the cumulative results showed a statistically significant difference in favor of TR 12 weeks after RP (OR 4.53, 95% CI 1.62 to 12.63; P = 0.004). The overall cumulative results showed a statistically significant difference in favor of TR 12 weeks after RP (OR 4.33, 95% CI 2.01–9.33; P < 0.001) (Fig. 5).

Return to continence at 24 weeks

Seven trials [10, 1820, 2527] reported the number of people returning to continence at 24 weeks. In the 0-pad subgroup, the cumulative results showed a statistically significant difference between the TR and nonTR groups in terms of return to continence at 24 weeks (OR 2.41, 95% CI 1.17 to 4.97; P = 0.02). In the 0–1 safety pad subgroup, the cumulative results showed a statistically significant difference in favor of TR 24 weeks after RP (OR 5.02, 95% CI 1.36 to 18.45; P = 0.02). The overall cumulative results showed a statistically significant difference in favor of TR 24 weeks after RP (OR 3.83, 95% CI 1.54–9.55; P = 0.004) (Fig. 6).

Return to continence at 52 weeks

Five studies [10, 18, 19, 25, 26] reported the number of people returning to continence at 52 weeks. In the 0-pad subgroup, the cumulative results showed no statistically significant difference between the TR and nonTR groups in terms of return to continence at 52 weeks (OR 2.20, 95% CI 0.63 to 7.61; P = 0.21). In the 0–1 safety pad subgroup, the cumulative results showed a statistically significant difference in favor of TR 52 weeks after RP (OR 4.63, 95% CI 1.83 to 11.72; P = 0.001). The overall cumulative results showed a statistically significant difference in favor of TR 52 weeks after RP (OR 4.10, 95% CI 1.80–9.38; P < 0.001) (Fig. 7).

Positive surgical margin rate

The positive surgical margin (PSM) rates of all enrolled trials are summarized in Table 4. In the total pathological stage subgroup, the pooled results demonstrated that there was no significant difference between the two groups (OR 1.11, 95% CI 0.70 to 1.77, P = 0.65). In the pT2 subgroup, the pooled results demonstrated that there was also no significant difference between the two groups (OR 1.61, 95% CI 0.83 to 3.11, P = 0.16). The pooled results of both subgroups indicated that there was no significant difference between the two groups (OR 1.27, 96% CI 0.87 to 1.85; P = 0.21) (Fig. 8).

Operation time, estimated blood loss, duration of catheterization, and complication rate

The perioperative outcome measures and complications are summarized in Table 4. The pooled results demonstrated that there was no significant difference between the two groups in terms of operative time (OR 8.93, 95% CI − 1.41 to 19.27, P = 0.09) (Fig. 9a), estimated blood loss (OR 3.37, 95% CI − 30.87 to 37.62, P = 0.85) (Fig. 9b), and duration of catheterization (OR − 0.78, 95% CI − 2.15 to 0.59, P = 0.26) (Fig. 9c). The complications of the seven trials are summarized in Table 4. The pooled results demonstrated that there was no significant difference between the two groups in terms of complications (OR 0.54, 95% CI 0.19 to 1.54; P = 0.25) (Fig. 9d). The cumulative results demonstrated that the TR technique is a simple method associated with early recovery from UI with no increase in operation time, estimated blood loss, duration of catheterization, and complication rate.

Discussion

UI plays an important role in reducing the QoL and raising the cost of care after RP [18]. Several technical modifications have been used to improve postoperative incontinence. However, variability in the rate of UI following RP remains one of the most important and significant functional complications.
In our meta-analysis, TR appeared to improve not only short-term urinary continence but also long-term urinary continence. To the best of our knowledge, the usefulness of the TR technique for improving long-term urinary continence remains controversial. Our meta-analysis demonstrated statistically significant differences in favor of the TR technique for urinary continence recovery. No statistically significant differences between the TR and nonTR groups were also observed for PSM rate, operation time, estimated blood loss, duration of catheterization, or complication rate.
The prevalence of UI after RP is significantly affected by participant preoperative demographics, surgeon experience, surgical technique, definition of continence, data collection tools, and differences in follow-up intervals [28] (Tables 3, 4, 5, and 6). Specifically, the continence rates varied, and there were discrepancies in the definition of continence. Menon et al. [22] found that 7-day urinary continence rates were 20 versus 16% in cases using a no-pad definition and 54 versus 51% in cases using a 0–1 for safety definition for patients underwent TR and nonTR, respectively. The 31-day urinary continence rates were 42 versus 80% in cases using a no-pad definition and 47 versus 74% in cases using a 0–1 pad for patients underwent TR and nonTR, respectively. However, a multicenter study is needed to externally validate these data.
There were several limitations in this study. First, the technique of TR was not standardized in all studies. The differences in surgical techniques for each surgical reconstruction process were reported accordingly. Student et al. [27] sutured the arcus tendineus to the bladder neck served as the anterior fixation and formed the dorsal support for the urethrovesical anastomosis using the fibers of the median dorsal raphe, retrotrigonal layer, Denonvillier’s fascia, and the levator ani muscle. Liao et al. [19] began the total reconstruction with posterior reconstruction that was accomplished by suturing the bladder musculature, Denonvillier’s fascia, and musculofascial plate posterior to the urethra. Then the arcus tendineus and puboprostatic plate were reattached to the bladder neck. Second, the definition of urinary continence recovery was not uniform in every study. Different methods were used to evaluate urinary continence recovery including the number of pads; pad tests; pad weight; the International Consortium on Incontinence Questionnaire, short form (ICIQ-SF); International Prostate System Score (IPSS); International Index of Erectile Function (IIEF-5) questionnaire; and European prospective investigation into cancer and nutrition (EPIC) questionnaire. Third, the different study designs could have influenced the outcomes of this study. A nerve-sparing technique was used in the surgical procedure by Liao et al. [19] and Atug et al. [25], while a different nerve-sparing technique was used by Menon et al. [22] and Sammon et al. [23]. Because of the small number of reported trials, we did not distinguish RCTs from retrospective studies.

Conclusions

TR appeared to be associated with an advantage for urinary continence recovery 1, 2, 4, 12, 24, and 52 weeks after RP. For the first time, our meta-analysis demonstrated a significant advantage in favor of TR in terms of both short- and long-term (1, 2, 4, 12, 24, and 52 weeks) urinary continence recovery. However, this result needs to be validated in further multicenter, prospective, randomized, controlled studies. Methodological factors need to be taken into account when interpreting the cumulative results.

Acknowledgements

Not applicable

Funding

This work was supported by the Natural Science Foundation of Fujian Province, China (No. 2015J01393).

Availability of data and materials

All the data used in the study can be obtained from the original articles.
Not applicable
Not applicable

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Literatur
1.
Zurück zum Zitat Wu YP, Lin TT, Chen SH, Xu N, Wei Y, Huang JB, Sun XL, Zheng QS, Xue XY, Li XD. Comparison of the efficacy and feasibility of en bloc transurethral resection of bladder tumor versus conventional transurethral resection of bladder tumor: a meta-analysis. Medicine (Baltimore). 2016;95:e5372.CrossRef Wu YP, Lin TT, Chen SH, Xu N, Wei Y, Huang JB, Sun XL, Zheng QS, Xue XY, Li XD. Comparison of the efficacy and feasibility of en bloc transurethral resection of bladder tumor versus conventional transurethral resection of bladder tumor: a meta-analysis. Medicine (Baltimore). 2016;95:e5372.CrossRef
2.
Zurück zum Zitat Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2016;71:630–42. Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2016;71:630–42.
3.
Zurück zum Zitat Ficarra V, Novara G, Artibani W, Cestari A, Galfano A, Graefen M, Guazzoni G, Guillonneau B, Menon M, Montorsi F, et al. Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies. Eur Urol. 2009;55:1037–63.CrossRefPubMed Ficarra V, Novara G, Artibani W, Cestari A, Galfano A, Graefen M, Guazzoni G, Guillonneau B, Menon M, Montorsi F, et al. Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies. Eur Urol. 2009;55:1037–63.CrossRefPubMed
4.
Zurück zum Zitat Menon M, Shrivastava A, Kaul S, Badani KK, Fumo M, Bhandari M, Peabody JO. Vattikuti Institute prostatectomy: contemporary technique and analysis of results. Eur Urol. 2007;51:648–57.CrossRefPubMed Menon M, Shrivastava A, Kaul S, Badani KK, Fumo M, Bhandari M, Peabody JO. Vattikuti Institute prostatectomy: contemporary technique and analysis of results. Eur Urol. 2007;51:648–57.CrossRefPubMed
5.
Zurück zum Zitat Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250–61. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250–61.
6.
Zurück zum Zitat Jonler M, Madsen FA, Rhodes PR, Sall M, Messing EM, Bruskewitz RC. A prospective study of quantification of urinary incontinence and quality of life in patients undergoing radical retropubic prostatectomy. Urology. 1996;48:433–40.CrossRefPubMed Jonler M, Madsen FA, Rhodes PR, Sall M, Messing EM, Bruskewitz RC. A prospective study of quantification of urinary incontinence and quality of life in patients undergoing radical retropubic prostatectomy. Urology. 1996;48:433–40.CrossRefPubMed
7.
Zurück zum Zitat Mungovan SF, Sandhu JS, Akin O, Smart NA, Graham PL, Patel MI. Preoperative membranous urethral length measurement and continence recovery following radical prostatectomy: a systematic review and meta-analysis. Eur Urol. 2016;71:368–78. Mungovan SF, Sandhu JS, Akin O, Smart NA, Graham PL, Patel MI. Preoperative membranous urethral length measurement and continence recovery following radical prostatectomy: a systematic review and meta-analysis. Eur Urol. 2016;71:368–78.
8.
Zurück zum Zitat Hoshi A, Usui Y, Shimizu Y, Tomonaga T, Kawakami M, Nakajima N, Hanai K, Nomoto T, Terachi T. Dorsal vein complex preserving technique for intrafascial nerve-sparing laparoscopic radical prostatectomy. Int J Urol. 2013;20:493–500.CrossRefPubMed Hoshi A, Usui Y, Shimizu Y, Tomonaga T, Kawakami M, Nakajima N, Hanai K, Nomoto T, Terachi T. Dorsal vein complex preserving technique for intrafascial nerve-sparing laparoscopic radical prostatectomy. Int J Urol. 2013;20:493–500.CrossRefPubMed
9.
Zurück zum Zitat Stolzenburg JU, Rabenalt R, Do M, Schwalenberg T, Winkler M, Dietel A, Liatsikos E. Intrafascial nerve-sparing endoscopic extraperitoneal radical prostatectomy. Eur Urol. 2008;53:931–40.CrossRefPubMed Stolzenburg JU, Rabenalt R, Do M, Schwalenberg T, Winkler M, Dietel A, Liatsikos E. Intrafascial nerve-sparing endoscopic extraperitoneal radical prostatectomy. Eur Urol. 2008;53:931–40.CrossRefPubMed
10.
Zurück zum Zitat Hoshi A, Nitta M, Shimizu Y, Higure T, Kawakami M, Nakajima N, Hanai K, Nomoto T, Usui Y, Terachi T. Total pelvic floor reconstruction during non-nerve-sparing laparoscopic radical prostatectomy: impact on early recovery of urinary continence. Int J Urol. 2014;21:1132–7.CrossRefPubMed Hoshi A, Nitta M, Shimizu Y, Higure T, Kawakami M, Nakajima N, Hanai K, Nomoto T, Usui Y, Terachi T. Total pelvic floor reconstruction during non-nerve-sparing laparoscopic radical prostatectomy: impact on early recovery of urinary continence. Int J Urol. 2014;21:1132–7.CrossRefPubMed
11.
Zurück zum Zitat Stolzenburg JU, Liatsikos EN, Rabenalt R, Do M, Sakelaropoulos G, Horn LC, Truss MC. Nerve sparing endoscopic extraperitoneal radical prostatectomy—effect of puboprostatic ligament preservation on early continence and positive margins. Eur Urol. 2006;49:103–11. discussion 111–102 Stolzenburg JU, Liatsikos EN, Rabenalt R, Do M, Sakelaropoulos G, Horn LC, Truss MC. Nerve sparing endoscopic extraperitoneal radical prostatectomy—effect of puboprostatic ligament preservation on early continence and positive margins. Eur Urol. 2006;49:103–11. discussion 111–102
12.
Zurück zum Zitat Patel VR, Coelho RF, Palmer KJ, Rocco B. Periurethral suspension stitch during robot-assisted laparoscopic radical prostatectomy: description of the technique and continence outcomes. Eur Urol. 2009;56:472–8. Patel VR, Coelho RF, Palmer KJ, Rocco B. Periurethral suspension stitch during robot-assisted laparoscopic radical prostatectomy: description of the technique and continence outcomes. Eur Urol. 2009;56:472–8.
13.
Zurück zum Zitat Porpiglia F, Fiori C, Grande S, Morra I, Scarpa RM. Selective versus standard ligature of the deep venous complex during laparoscopic radical prostatectomy: effects on continence, blood loss, and margin status. Eur Urol. 2009;55:1377–83.CrossRefPubMed Porpiglia F, Fiori C, Grande S, Morra I, Scarpa RM. Selective versus standard ligature of the deep venous complex during laparoscopic radical prostatectomy: effects on continence, blood loss, and margin status. Eur Urol. 2009;55:1377–83.CrossRefPubMed
14.
Zurück zum Zitat Joshi N, de Blok W, van Muilekom E, van der Poel H. Impact of posterior musculofascial reconstruction on early continence after robot-assisted laparoscopic radical prostatectomy: results of a prospective parallel group trial. Eur Urol. 2010;58:84–9.CrossRefPubMed Joshi N, de Blok W, van Muilekom E, van der Poel H. Impact of posterior musculofascial reconstruction on early continence after robot-assisted laparoscopic radical prostatectomy: results of a prospective parallel group trial. Eur Urol. 2010;58:84–9.CrossRefPubMed
15.
Zurück zum Zitat Nguyen MM, Kamoi K, Stein RJ, Aron M, Hafron JM, Turna B, Myers RP, Gill IS. Early continence outcomes of posterior musculofascial plate reconstruction during robotic and laparoscopic prostatectomy. BJU Int. 2008;101:1135–9.CrossRefPubMed Nguyen MM, Kamoi K, Stein RJ, Aron M, Hafron JM, Turna B, Myers RP, Gill IS. Early continence outcomes of posterior musculofascial plate reconstruction during robotic and laparoscopic prostatectomy. BJU Int. 2008;101:1135–9.CrossRefPubMed
16.
Zurück zum Zitat Rocco B, Gregori A, Stener S, Santoro L, Bozzola A, Galli S, Knez R, Scieri F, Scaburri A, Gaboardi F. Posterior reconstruction of the rhabdosphincter allows a rapid recovery of continence after transperitoneal videolaparoscopic radical prostatectomy. Eur Urol. 2007;51:996–1003.CrossRefPubMed Rocco B, Gregori A, Stener S, Santoro L, Bozzola A, Galli S, Knez R, Scieri F, Scaburri A, Gaboardi F. Posterior reconstruction of the rhabdosphincter allows a rapid recovery of continence after transperitoneal videolaparoscopic radical prostatectomy. Eur Urol. 2007;51:996–1003.CrossRefPubMed
17.
Zurück zum Zitat Coelho RF, Chauhan S, Orvieto MA, Sivaraman A, Palmer KJ, Coughlin G, Patel VR. Influence of modified posterior reconstruction of the rhabdosphincter on early recovery of continence and anastomotic leakage rates after robot-assisted radical prostatectomy. Eur Urol. 2011;59:72–80.CrossRefPubMed Coelho RF, Chauhan S, Orvieto MA, Sivaraman A, Palmer KJ, Coughlin G, Patel VR. Influence of modified posterior reconstruction of the rhabdosphincter on early recovery of continence and anastomotic leakage rates after robot-assisted radical prostatectomy. Eur Urol. 2011;59:72–80.CrossRefPubMed
18.
Zurück zum Zitat Tewari A, Jhaveri J, Rao S, Yadav R, Bartsch G, Te A, Ioffe E, Pineda M, Mudaliar S, Nguyen L, et al. Total reconstruction of the vesico-urethral junction. BJU Int. 2008;101:871–7.CrossRefPubMed Tewari A, Jhaveri J, Rao S, Yadav R, Bartsch G, Te A, Ioffe E, Pineda M, Mudaliar S, Nguyen L, et al. Total reconstruction of the vesico-urethral junction. BJU Int. 2008;101:871–7.CrossRefPubMed
19.
Zurück zum Zitat Liao X, Qiao P, Tan Z, Shi H, Xing N. “Total reconstruction” of the urethrovesical anastomosis contributes to early urinary continence in laparoscopic radical prostatectomy. Int Braz J Urol. 2016;42:215–22.CrossRefPubMedPubMedCentral Liao X, Qiao P, Tan Z, Shi H, Xing N. “Total reconstruction” of the urethrovesical anastomosis contributes to early urinary continence in laparoscopic radical prostatectomy. Int Braz J Urol. 2016;42:215–22.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Hurtes X, Roupret M, Vaessen C, Pereira H, Faivre d'Arcier B, Cormier L, Bruyere F. Anterior suspension combined with posterior reconstruction during robot-assisted laparoscopic prostatectomy improves early return of urinary continence: a prospective randomized multicentre trial. BJU Int. 2012;110:875–83. Hurtes X, Roupret M, Vaessen C, Pereira H, Faivre d'Arcier B, Cormier L, Bruyere F. Anterior suspension combined with posterior reconstruction during robot-assisted laparoscopic prostatectomy improves early return of urinary continence: a prospective randomized multicentre trial. BJU Int. 2012;110:875–83.
21.
Zurück zum Zitat Koliakos N, Mottrie A, Buffi N, De Naeyer G, Willemsen P, Fonteyne E. Posterior and anterior fixation of the urethra during robotic prostatectomy improves early continence rates. Scand J Urol Nephrol. 2010;44:5–10.CrossRefPubMed Koliakos N, Mottrie A, Buffi N, De Naeyer G, Willemsen P, Fonteyne E. Posterior and anterior fixation of the urethra during robotic prostatectomy improves early continence rates. Scand J Urol Nephrol. 2010;44:5–10.CrossRefPubMed
22.
Zurück zum Zitat Menon M, Muhletaler F, Campos M, Peabody JO. Assessment of early continence after reconstruction of the periprostatic tissues in patients undergoing computer assisted (robotic) prostatectomy: results of a 2 group parallel randomized controlled trial. J Urol. 2008;180:1018–23.CrossRefPubMed Menon M, Muhletaler F, Campos M, Peabody JO. Assessment of early continence after reconstruction of the periprostatic tissues in patients undergoing computer assisted (robotic) prostatectomy: results of a 2 group parallel randomized controlled trial. J Urol. 2008;180:1018–23.CrossRefPubMed
23.
Zurück zum Zitat Sammon JD, Muhletaler F, Peabody JO, Diaz-Insua M, Satyanaryana R, Menon M. Long-term functional urinary outcomes comparing single- vs double-layer urethrovesical anastomosis: two-year follow-up of a two-group parallel randomized controlled trial. Urology. 2010;76:1102–7.CrossRefPubMed Sammon JD, Muhletaler F, Peabody JO, Diaz-Insua M, Satyanaryana R, Menon M. Long-term functional urinary outcomes comparing single- vs double-layer urethrovesical anastomosis: two-year follow-up of a two-group parallel randomized controlled trial. Urology. 2010;76:1102–7.CrossRefPubMed
24.
Zurück zum Zitat Liu W, Galik E, Boltz M, Nahm ES, Resnick B. Optimizing eating performance for older adults with dementia living in long-term care: a systematic review. Worldviews Evid-Based Nurs. 2015;12:228–35. Liu W, Galik E, Boltz M, Nahm ES, Resnick B. Optimizing eating performance for older adults with dementia living in long-term care: a systematic review. Worldviews Evid-Based Nurs. 2015;12:228–35.
25.
Zurück zum Zitat Atug F, Kural AR, Tufek I, Srivastav S, Akpinar H. Anterior and posterior reconstruction technique and its impact on early return of continence after robot-assisted radical prostatectomy. J Endourol. 2012;26:381–6.CrossRefPubMed Atug F, Kural AR, Tufek I, Srivastav S, Akpinar H. Anterior and posterior reconstruction technique and its impact on early return of continence after robot-assisted radical prostatectomy. J Endourol. 2012;26:381–6.CrossRefPubMed
26.
Zurück zum Zitat Tan G, Srivastava A, Grover S, Peters D, Dorsey P Jr, Scott A, Jhaveri J, Tilki D, Te A, Tewari A. Optimizing vesicourethral anastomosis healing after robot-assisted laparoscopic radical prostatectomy: lessons learned from three techniques in 1900 patients. J Endourol. 2010;24:1975–83.CrossRefPubMed Tan G, Srivastava A, Grover S, Peters D, Dorsey P Jr, Scott A, Jhaveri J, Tilki D, Te A, Tewari A. Optimizing vesicourethral anastomosis healing after robot-assisted laparoscopic radical prostatectomy: lessons learned from three techniques in 1900 patients. J Endourol. 2010;24:1975–83.CrossRefPubMed
27.
Zurück zum Zitat Student V Jr, Vidlar A, Grepl M, Hartmann I, Buresova E, Student V. Advanced reconstruction of vesicourethral support (ARVUS) during robot-assisted radical prostatectomy: one-year functional outcomes in a two-group randomised controlled trial. Eur Urol. 2017;71:822–30.CrossRefPubMed Student V Jr, Vidlar A, Grepl M, Hartmann I, Buresova E, Student V. Advanced reconstruction of vesicourethral support (ARVUS) during robot-assisted radical prostatectomy: one-year functional outcomes in a two-group randomised controlled trial. Eur Urol. 2017;71:822–30.CrossRefPubMed
28.
Zurück zum Zitat Ficarra V, Novara G, Rosen RC, Artibani W, Carroll PR, Costello A, Menon M, Montorsi F, Patel VR, Stolzenburg JU, et al. Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol. 2012;62:405–17.CrossRefPubMed Ficarra V, Novara G, Rosen RC, Artibani W, Carroll PR, Costello A, Menon M, Montorsi F, Patel VR, Stolzenburg JU, et al. Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol. 2012;62:405–17.CrossRefPubMed
Metadaten
Titel
The efficacy and feasibility of total reconstruction versus nontotal reconstruction of the pelvic floor on short-term and long-term urinary continence rates after radical prostatectomy: a meta-analysis
verfasst von
Yu-Peng Wu
Ning Xu
Shi-Tao Wang
Shao-Hao Chen
Yun-Zhi Lin
Xiao-Dong Li
Qing-Shui Zheng
Yong Wei
Xue-Yi Xue
Publikationsdatum
01.12.2017
Verlag
BioMed Central
Erschienen in
World Journal of Surgical Oncology / Ausgabe 1/2017
Elektronische ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-017-1296-z

Weitere Artikel der Ausgabe 1/2017

World Journal of Surgical Oncology 1/2017 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.